- Oops!Something went wrong.Please try again later.
NEW YORK, December 02, 2021--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instadose Pharma Corp. ("Instadose" or the "Company") (Other OTC: INSD) on behalf of Instadose stockholders. Our investigation concerns whether Instadose has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On November 23, 2021, the U.S. Securities and Exchange Commission ("SEC") announced a temporary suspension in the trading of Instadose securities due to concerns regarding the adequacy and accuracy of information about the Company in the marketplace. The SEC specifically noted stock price and volume increases of Instadose stock unsupported by the Company’s assets and financial information, trading that may be associated with individuals related to a control person at the Company, and operations at the Company’s Canadian affiliate.
On this news, the Company’s share price declined by $3.69 per share, or approximately 13%, from $28.30 per share to close at $24.61 per share on November 23, 2021.
If you purchased or otherwise acquired Instadose shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201006248/en/